SCI REP:房颤、心房增大与左心室几何重构的关系!

2018-04-23 xing.T MedSci原创

总之,房颤的患病率随着LV几何重构的模式而增加,并且与左心房大小和LVEF相关。

近日,Scientific reports杂志上发表了一篇研究文章,该研究旨在通过日本医院为基础的人群探讨房颤与左心室(LV)几何形状之间的关系。

研究人员回顾性地分析了2013年期间同时接受经胸超声心动图(TTE)和心电图检查的4444例患者。共计有430例既往有心肌梗死(n=419)和无体表面积(n=11)数据的患者被排除该研究。研究人员计算了LV质量指数(LVMI)和相对室壁厚度(RWT),并将4014例患者分为以下四组:正常几何形状组(n=3046)、向心性重构组(正常LVMI和高RWT,n=437)、向心性肥大组(高LVMI和高RWT,n=149)和离心性重构组(高LVMI和正常RWT,n=382)。

研究人员发现正常几何形状组、向心性重构组、向心性肥大组和离心性肥厚组的平均左房容积指数(LAVI)分别为22.5、23.8、33.3和37μm/m2。平均LV射血分数(LVEF)分别为62.7、62.6、60.8和53.8%,而正常几何形状组、向心性重构组、向心性肥大组和离心性肥厚组患者房颤的患病率分别为10.4%、10.5%、14.8%和16.8%。

总之,房颤的患病率随着LV几何重构的模式而增加,并且与左心房大小和LVEF相关。

原始出处:

Yuta Seko,et al. Association between atrial fibrillation, atrial enlargement, and left ventricular geometric remodeling.Scientific reports.2018. https://www.nature.com/articles/s41598-018-24875-1

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1413226, encodeId=f267141322692, content=<a href='/topic/show?id=1d7e48033f5' target=_blank style='color:#2F92EE;'>#左心室#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48033, encryptionId=1d7e48033f5, topicName=左心室)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15012955474, createdName=wushaoling, createdTime=Wed Apr 25 11:14:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626876, encodeId=a02b16268e6e1, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Wed Apr 25 11:14:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308763, encodeId=40fb308e63af, content=好文献.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Tue Apr 24 07:45:13 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308625, encodeId=ab87308625af, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Apr 23 21:04:36 CST 2018, time=2018-04-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1413226, encodeId=f267141322692, content=<a href='/topic/show?id=1d7e48033f5' target=_blank style='color:#2F92EE;'>#左心室#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48033, encryptionId=1d7e48033f5, topicName=左心室)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15012955474, createdName=wushaoling, createdTime=Wed Apr 25 11:14:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626876, encodeId=a02b16268e6e1, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Wed Apr 25 11:14:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308763, encodeId=40fb308e63af, content=好文献.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Tue Apr 24 07:45:13 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308625, encodeId=ab87308625af, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Apr 23 21:04:36 CST 2018, time=2018-04-23, status=1, ipAttribution=)]
    2018-04-25 sodoo
  3. [GetPortalCommentsPageByObjectIdResponse(id=1413226, encodeId=f267141322692, content=<a href='/topic/show?id=1d7e48033f5' target=_blank style='color:#2F92EE;'>#左心室#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48033, encryptionId=1d7e48033f5, topicName=左心室)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15012955474, createdName=wushaoling, createdTime=Wed Apr 25 11:14:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626876, encodeId=a02b16268e6e1, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Wed Apr 25 11:14:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308763, encodeId=40fb308e63af, content=好文献.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Tue Apr 24 07:45:13 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308625, encodeId=ab87308625af, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Apr 23 21:04:36 CST 2018, time=2018-04-23, status=1, ipAttribution=)]
    2018-04-24 张新亮1853311252142e2fm

    好文献.学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1413226, encodeId=f267141322692, content=<a href='/topic/show?id=1d7e48033f5' target=_blank style='color:#2F92EE;'>#左心室#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48033, encryptionId=1d7e48033f5, topicName=左心室)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15012955474, createdName=wushaoling, createdTime=Wed Apr 25 11:14:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626876, encodeId=a02b16268e6e1, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Wed Apr 25 11:14:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308763, encodeId=40fb308e63af, content=好文献.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Tue Apr 24 07:45:13 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308625, encodeId=ab87308625af, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Apr 23 21:04:36 CST 2018, time=2018-04-23, status=1, ipAttribution=)]
    2018-04-23 天地飞扬

    了解一下.谢谢分享!

    0

相关资讯

JAHA:BMI与房颤的发生风险呈正相关

房颤的发病率逐年增加,体重指数(BMI)是房颤的危险因素,然而,性别在BMI对房颤影响中的作用尚不清楚。本研究纳入了Troms?第四次临床研究中的24799名研究对象(平均年龄为45.5±14.2岁,女性占52.9%),经过平均15.7±5.5年时间的随访,有811名(6.2%)女性和918名(7.9%)男性发展为房颤,在男性中,低的BMI可以降低房颤的发生风险,而高BMI会增加房颤的风险(HR:

JAHA:焦虑可增加房颤患者的卒中发生风险!

焦虑和抑郁会加重许多心血管疾病的预后结局,然而其是否会影响房颤患者的预后尚属未知。本研究的目的旨在评估房颤患者中焦虑和/或抑郁是否与卒中和出血事件的发生相关。本研究纳入了2004年至2007年WAVE数据库中接受华法林治疗的房颤患者,通过电子病历记录对患者进行焦虑和抑郁的诊断。最终共纳入了25570名房颤患者,其中490名患者出现了卒中或脑出血(1.52次/100人年),多变量分析后发现,焦虑会增

Circulationg:房颤诊疗存在重大疏漏!不能仅以房颤发作或终止作为评价标准,要重视房颤负荷

昨日,Circulation杂志在线发表科学声明,指出目前临床多根据房颤类型进行相应的研究,包括阵发性与非阵发性、持续性或永久性房颤,推荐使用危险评分(CHA2DS2-VASc)进行抗凝治疗。但这存在重大疏漏:如果仅以有房颤或无房颤来描述太片面!今后要考虑房颤负荷问题。

JAHA:外周动脉疾病与房颤发生之间的相关性!

由此可见,较低ABI诊断的外周动脉疾病,包括边界性ABI,是房颤一个较弱的危险因素。ABI>1.4与房颤风险增加无关。外周动脉疾病与房颤之间的关系主要是由传统的动脉粥样硬化危险因素来解释。

JAHA:新型口服抗凝剂vs.华法林治疗房颤和瓣膜性心脏病的安全性和疗效

新型口服非维生素K抗凝剂是预防全身血栓安全有效的选择。

Circulation:房颤女性口服抗凝决策:CHA2DS2-VA or CHA2DS2-VASc评分?

2018年2月,发表在《Circulation》的一项由丹麦和英国科学家进行的研究考察,女性性别是房颤患者卒中的风险调节因素而非风险因素:我们应该使用CHA2DS2-VA评分而非CHA2DS2-VASc评分?